Exelixis, Inc. (NASDAQ:EXEL) Director Bob Oliver Sells 18,647 Shares of Stock

Exelixis, Inc. (NASDAQ:EXEL) Director Bob Oliver sold 18,647 shares of Exelixis stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $37.25, for a total transaction of $694,600.75. Following the completion of the transaction, the director now directly owns 33,514 shares in the company, valued at $1,248,396.50. This represents a 35.75 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Exelixis Stock Performance

NASDAQ:EXEL opened at $37.53 on Thursday. The company has a fifty day moving average of $34.34 and a two-hundred day moving average of $31.50. The stock has a market capitalization of $10.50 billion, a PE ratio of 21.20, a P/E/G ratio of 1.13 and a beta of 0.53. Exelixis, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $37.64.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Research analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Institutional Trading of Exelixis

A number of hedge funds have recently bought and sold shares of EXEL. Forum Financial Management LP acquired a new position in shares of Exelixis during the 4th quarter worth approximately $241,000. GF Fund Management CO. LTD. acquired a new stake in shares of Exelixis in the fourth quarter valued at approximately $200,000. Neo Ivy Capital Management lifted its position in Exelixis by 427.8% during the fourth quarter. Neo Ivy Capital Management now owns 53,892 shares of the biotechnology company’s stock worth $1,794,000 after buying an additional 43,682 shares in the last quarter. JT Stratford LLC acquired a new position in Exelixis during the fourth quarter worth $288,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Exelixis by 4.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 844,345 shares of the biotechnology company’s stock valued at $28,117,000 after buying an additional 33,804 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $34.00 target price on shares of Exelixis in a research note on Wednesday, October 30th. Stephens reiterated an “equal weight” rating and set a $29.00 price objective on shares of Exelixis in a research note on Wednesday, February 12th. Bank of America downgraded Exelixis from a “buy” rating to a “neutral” rating and upped their target price for the company from $35.00 to $39.00 in a research report on Tuesday, December 17th. Citigroup lifted their price target on Exelixis from $38.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, February 12th. Finally, Wells Fargo & Company lowered Exelixis from an “overweight” rating to an “equal weight” rating and set a $36.00 price objective on the stock. in a report on Monday. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $37.24.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.